GlassScriptPhysician profile
Johnson L Gomez
NPI 1649534918
$2,180.93
in general payments reported to CMS, 2019-2025
26 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $37.21 · 2021: $84.99 · 2022: $222 · 2023: $627 · 2024: $627 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645 · Education: $77.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.59 |
| Education | $77.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $247.42 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $209.99 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $184.38 | 2022-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $163.61 | 2019-2024 | Veltassa |
| Amgen INC. | $135.37 | 2023-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $134.95 | 2023-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $127.28 | 2023 | Acthar |
| Ardelyx, INC. | $121.73 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $88.93 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $79.80 | 2020-2025 | |
| Horizon Therapeutics Plc | $74.56 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.91 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $67.50 | 2023-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $66.07 | 2024-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $64.32 | 2023-2025 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51.66 | 2019-2023 | Xarelto |
| Ani Pharmaceuticals, INC. | $47.34 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $42.65 | 2022-2023 | Tarpeyo |
| Kyowa Kirin, INC. | $41.79 | 2024-2025 | Crysvita |
| Allergan, INC. | $36.42 | 2019 | |
| Merck Sharp & Dohme LLC | $32.75 | 2019 | |
| Daiichi Sankyo INC. | $24.58 | 2024 | Injectafer |
| Lilly USA, LLC | $21.27 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $17.73 | 2023 | Benlysta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.59 | 2019 | |
| Scpharmaceuticals INC. | $15.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnson Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.